Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes

Prostate Cancer and Prostatic Diseases volume 12, pages 269–276 (2009)Cite this article

Abstract

We assessed self-reported health-related quality of life (HRQoL) and longitudinal changes in sex hormones among 86 prostate cancer (PCa) patients without distant metastases 5 years after radiotherapy (RT) combined with ongoing antiandrogen (AA) treatment. HRQoL outcomes were compared with scores from age-matched controls without a cancer diagnosis (NORM). Compared with NORM, patients scored statistically (P<0.05) and clinically (effect size ⩾0.4) lower on sexual domains, and statistically (P<0.05) lower on physical function and vitality. Estimated free testosterone and measured serum estradiol had increased from baseline in most patients, but did not correlate with HRQoL outcomes 5 years after the start of treatment.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Bestmann B, Loetters C, Diemer T, Weidner W, Kuchler T, Rohde V . Prostate-specific symptoms of prostate cancer in a German general population. Prostate Cancer Prostatic Dis 2006; 10: 52–59.

    Article  PubMed  Google Scholar 

  2. Fossa SD, Dahl AA, Loge JH . Fatigue, Anxiety, and Depression in Long-Term Survivors of Testicular Cancer. J Clin Oncol 2003; 21: 1249–1254.

    Article  PubMed  Google Scholar 

  3. See WA, Tyrrell CJ . The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol 2006; 132 (Suppl 1): S7–S16.

    Article  CAS  PubMed  Google Scholar 

  4. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2008; 373: 301–308 e-pub ahead of print).

    Article  PubMed  Google Scholar 

  5. Alibhai SM, Gogov S, Allibhai Z . Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006; 60: 201–215.

    Article  PubMed  Google Scholar 

  6. Novak A, Brod M, Elbers J . Andropause and quality of life: findings from patient focus groups and clinical experts. Maturitas 2002; 43: 231–237.

    Article  CAS  PubMed  Google Scholar 

  7. Schroder FH, Collette L, de Reijke TM, Whelan P . Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer 2000; 82: 283–290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51: 389–396.

    Article  CAS  PubMed  Google Scholar 

  9. Iversen P . Quality of life issues relating to endocrine treatment options. Eur Urol 1999; 36 (Suppl 2): 20–26.

    Article  PubMed  Google Scholar 

  10. Mostofi FK, Davis Jr CJ, Sesterhenn IA . Pathology of carcinoma of the prostate. Cancer 1992; 70 (1 Suppl): 235–253.

    Article  CAS  PubMed  Google Scholar 

  11. Murphy GP, Busch C, Abrahamsson PA, Epstein JI, McNeal JE, Miller GJ et al. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12–13, 1993. Scand J Urol Nephrol Suppl 1994; 162: 7–42.

    CAS  PubMed  Google Scholar 

  12. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL . The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228–1242.

    Article  PubMed  Google Scholar 

  13. Paus E, Nilsson O, Bormer OP, Fossa SD, Otnes B, Skovlund E . Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. J Urol 1998; 159: 1599–1605.

    Article  CAS  PubMed  Google Scholar 

  14. Stewart AL, Hays RD, Ware Jr JE . The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26: 724–735.

    Article  CAS  PubMed  Google Scholar 

  15. Ware Jr JE, Snow KK, Kosinski M . SF-36 Health Survey: Manual and Interpretation Guide. QualityMetric Incorporated: Lincoln, RI, 2000.

    Google Scholar 

  16. Ware Jr JE, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 1167–1170.

    Article  PubMed  Google Scholar 

  17. Zigmond AS, Snaith RP . The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370.

    Article  CAS  PubMed  Google Scholar 

  18. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D et al. Development of a fatigue scale. J Psychosom Res 1993; 37: 147–153.

    Article  CAS  PubMed  Google Scholar 

  19. Pawlikowska T, Chalder T, Hirsch SR, Wallace P, Wright DJ, Wessely SC . Population based study of fatigue and psychological distress. BMJ 1994; 308: 763–766.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. O'Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA et al. A brief male sexual function inventory for urology. Urology 1995; 46: 697–706.

    Article  CAS  PubMed  Google Scholar 

  21. Mykletun A, Dahl AA, O'Leary MP, Fossa SD . Assessment of male sexual function by the Brief Sexual Function Inventory. BJU Int 2006; 97: 316–323.

    Article  PubMed  Google Scholar 

  22. Cohen J . Statistical power analysis fo the behavioural sciences, (2nd ed) Lawrence Earlbaum Associates: Hillsdale, NJ, 1998.

    Google Scholar 

  23. Lipsey MW, Wilson DB . Practical meta-analysis. Thousand Oaks, CA: SAGE publications, inc, 2001.

    Google Scholar 

  24. Thornton AA, Perez MA . Posttraumatic growth in prostate cancer survivors and their partners. Psychooncology 2006; 15: 285–296.

    Article  PubMed  Google Scholar 

  25. Korfage IJ, Essink-Bot ML, Borsboom GJ, Madalinska JB, Kirkels WJ, Habbema JD et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005; 116: 291–296.

    Article  CAS  PubMed  Google Scholar 

  26. Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR et al. Erectile Function Outcome Reporting After Clinically Localized Prostate Cancer Treatment. J Urol 2007; 178: 597–601.

    Article  PubMed  Google Scholar 

  27. Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P et al. Bicalutamide (′Casodex′) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 2005; 76: 4–10.

    Article  CAS  PubMed  Google Scholar 

  28. Iversen P . The third analysis of the bicalutamide Early Prostate Cancer programme. BJU Int 2006; 97: 438–439.

    Article  PubMed  Google Scholar 

  29. Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997; 32: 391–395.

    CAS  PubMed  Google Scholar 

  30. Eri LM, Haug E, Tveter KJ . Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia. Br J Urol 1995; 75: 335–340.

    Article  CAS  PubMed  Google Scholar 

  31. Byar DP . Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126–1130.

    Article  CAS  PubMed  Google Scholar 

  32. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247–254.

    Article  CAS  PubMed  Google Scholar 

  33. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW . Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289–295.

    CAS  PubMed  Google Scholar 

  34. Singh SM, Gauthier S, Labrie F . Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem 2000; 7: 211–247.

    Article  CAS  PubMed  Google Scholar 

  35. Kolvenbag GJ, Furr BJ, Blackledge GR . Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis 1998; 1: 307–314.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge Aasmund Berner, MD, PhD for Gleason grading and professor Elisabeth Paus, PhD for her efforts related to PSA measurements.

Author information

Authors and Affiliations

  1. Faculty Division the Norwegian Radium Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway

    A Berg, A A Dahl, Ø S Bruland, M S Aanensen & S D Fosså

  2. Division of Cancer Medicine and Radiotherapy, The Norwegian Radium Hospital, Oslo, Norway

    A A Dahl, Ø S Bruland & S D Fosså

  3. Division of Laboratory Medicine, Rikshospitalet University Hospital, Oslo, Norway

    T Bjøro

  4. Faculty Division Rikshospitalet, Faculty of Medicine, University of Oslo, Oslo, Norway

    T Bjøro

Authors
  1. A Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A A Dahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ø S Bruland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Bjøro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M S Aanensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S D Fosså
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Berg.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Berg, A., Dahl, A., Bruland, Ø. et al. Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes. Prostate Cancer Prostatic Dis 12, 269–276 (2009). https://doi.org/10.1038/pcan.2009.8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.8

Keywords

  • antiandrogens
  • health-related quality of life
  • radiotherapy

This article is cited by

Search

Advanced search

Quick links